Menu
home
about us
Investment Approach
Client Service Approach
Market Analysis Summary
Mission Statement
Value Proposition
Team Biographies
Firm ADV PDFs
Form CRS
Firm Brochure-Part 2A of Form ADV
Brochure Supplement Amit Stavinsky
Brochure Supplement Frank Parks
Brochure Supplement Dominick Savo
Brochure Supplement Richard Mason
Brochure Supplement Joe Estes
Brochure Supplement Jonathan Ezra
Statement Of Financial Strength
Job Opportunities
Tamar Advisors
Own Your Practice
Letter to Clients
member log-in
contact us
PRODUCTS
Fixed Income Portfolio (FIP)
FIP Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Market (TAM)
TAM sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Fund (TAF)
TAF sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Market Value Securities (MVS)
MVS Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Value (TAV)
TAV Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Municipal Bonds
Taxable Bonds
Par, Premium, and Discount Bonds
Rating and Analyzing Bonds
Refunding & Pre-refunding
Bond Yields
Yield Curve
Secured Bonds
Mortgage Bonds
Unsecured Bonds
Debentures
Subordinated Debentures
Zero-Coupon Bonds
Convertible Bonds
High Yield Dividend Stocks
Independent Money Managers
Fees & Compensation
Corporate Cash Management
Fees & Compensation
Estate Planning
Financial Planning
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
Professional Alliance Network
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
MUNICIPAL BONDS
Municipal Bond Presentation
About Us
The Management
Global Asset Allocation Products
FIP Program
Classifying Municipal Bonds
Revenue Bonds
Credit Factors Affecting General Obligation Bonds
Credit Factors Affecting the Quality of Local Municipal Bonds
Analyzing the Credit Quality of General Obligation Bonds
Analyzing the Credit Quality of Revenue Municipal Bonds
What We Buy Currently
What We Normally Don’t Buy
Municipal Bonds – Unique Asset Class
Default Rates
Yield Difference
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same-Day Allocation
TSL’s Turnkey Operation Platform
Sample Portfolio
Sample Portfolio Analysis
Classifying Municipal Bonds
Revenue Municipal Bonds
Types of Revenue Municipal Bonds
Industrial Development Revenue Bonds
Lease-back Bonds
Special Tax Bonds
NHA/PHA Bonds
Moral Obligation Bonds
Municipal Notes
TANs/RANs
BANs
CLNs/GANs
Variable Rate Bonds/Notes
Build America Bonds
Double-Barreled Bonds
Bond Index Components
Open-end-Closed-end-Indenture
Sinking Fund
Bond Contracts
Bond Indenture
Official Statement
Bond Issuance Process
Analyzing GO Bonds
Analyzing Revenue Bonds
Debt Ratios
General Price Analysis of Municipal Bonds
Liquidity
Interest Rate Risk
Credit Risk
Coupon Risk
Maturity Risk
Municipal Bond Insurance
Municipal Bonds Unique Asset Class
Default Rates
What We Buy Currently
What We Normally Don’t Buy
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same Day Allocation
Traditional Broker/Dealer Execution Flow
TSL's Turnkey Operation Platform
INDEX FUNDS
Total Asset Fund (TAF)
TAF sm Program
Services, Fees and Compensation
Account Requirements
Client Information
Client Contact with Portfolio Manager(s)
Additional Information
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
EVENTS
FIP
Event Schedule
Municipal Bond Presentation
TAM
Event Schedule
Total Asset Market (TAM sm) Presentation
TAF
Event Schedule
Total Asset Fund (TAF sm) Presentation
MVS
Event Schedule
Market Value Securities (MVS sm) Presentation
Featured Event
Calendar of Events
Events History
Investing During Uncertain Times
Read FULL Seminar Here
Tax-Free Income Seminar
Bond Fund Seminar
RSVP-Signup Form
MARKET RESEARCH
Featured Quarterly Newsletter
Featured Articles
Contrarian Notes Blog
home
about us
Investment Approach
Client Service Approach
Market Analysis Summary
Mission Statement
Value Proposition
Team Biographies
Firm ADV PDFs
Form CRS
Firm Brochure-Part 2A of Form ADV
Brochure Supplement Amit Stavinsky
Brochure Supplement Frank Parks
Brochure Supplement Dominick Savo
Brochure Supplement Richard Mason
Brochure Supplement Joe Estes
Brochure Supplement Jonathan Ezra
Statement Of Financial Strength
Job Opportunities
Tamar Advisors
Own Your Practice
Letter to Clients
member log-in
contact us
PRODUCTS
Fixed Income Portfolio (FIP)
FIP Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Market (TAM)
TAM sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Fund (TAF)
TAF sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Market Value Securities (MVS)
MVS Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Value (TAV)
TAV Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Municipal Bonds
Taxable Bonds
Par, Premium, and Discount Bonds
Rating and Analyzing Bonds
Refunding & Pre-refunding
Bond Yields
Yield Curve
Secured Bonds
Mortgage Bonds
Unsecured Bonds
Debentures
Subordinated Debentures
Zero-Coupon Bonds
Convertible Bonds
High Yield Dividend Stocks
Independent Money Managers
Fees & Compensation
Corporate Cash Management
Fees & Compensation
Estate Planning
Financial Planning
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
Professional Alliance Network
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
MUNICIPAL BONDS
Municipal Bond Presentation
About Us
The Management
Global Asset Allocation Products
FIP Program
Classifying Municipal Bonds
Revenue Bonds
Credit Factors Affecting General Obligation Bonds
Credit Factors Affecting the Quality of Local Municipal Bonds
Analyzing the Credit Quality of General Obligation Bonds
Analyzing the Credit Quality of Revenue Municipal Bonds
What We Normally Buy
What We Normally Don’t Buy
Municipal Bonds – Unique Asset Class
Default Rates
Yield Difference
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same-Day Allocation
TSL’s Turnkey Operation Platform
Classifying Municipal Bonds
Revenue Municipal Bonds
Types of Revenue Municipal Bonds
Industrial Development Revenue Bonds
Lease-back Bonds
Special Tax Bonds
NHA/PHA Bonds
Moral Obligation Bonds
Municipal Notes
TANs/RANs
BANs
CLNs/GANs
Variable Rate Bonds/Notes
Build America Bonds
Double-Barreled Bonds
Bond Index Components
Open-end-Closed-end-Indenture
Sinking Fund
Bond Contracts
Bond Indenture
Official Statement
Bond Issuance Process
Analyzing GO Bonds
Analyzing Revenue Bonds
Debt Ratios
General Price Analysis of Municipal Bonds
Liquidity
Interest Rate Risk
Credit Risk
Coupon Risk
Maturity Risk
Municipal Bond Insurance
Municipal Bonds Unique Asset Class
Default Rates
What We Buy Currently
What We Normally Don’t Buy
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same Day Allocation
Traditional Broker/Dealer Execution Flow
TSL's Turnkey Operation Platform
INDEX FUNDS
Total Asset Fund (TAF)
TAF® Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Additional Information
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
EVENTS
FIP
Event Schedule
TAM
Event Schedule
Total Asset Market (TAM sm) Presentation
TAF
Event Schedule
Total Asset Fund (TAF sm) Presentation
MVS
Event Schedule
Market Value Securities (MVS sm) Presentation
Featured Event
Calendar of Events
Events History
Investing During Uncertain Times
Read FULL Seminar Here
Tax-Free Income Seminar
Bond Fund Seminar
RSVP-Signup Form
MARKET RESEARCH
Featured Quarterly Newsletter
Featured Articles
Contrarian Notes Blog
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Medpace Holdings, Inc. - Common Stock
(NQ:
MEDP
)
567.56
-4.30 (-0.75%)
Streaming Delayed Price
Updated: 4:00 PM EST, Dec 26, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Medpace Holdings, Inc. - Common Stock
< Previous
1
2
3
4
5
6
7
8
9
...
12
13
Next >
2 Profitable Stocks to Keep an Eye On and 1 We Find Risky
December 11, 2025
While profitability is essential, it doesn’t guarantee long-term success. Some companies that rest on their margins will lose ground as competition intensifies - as Jeff Bezos said, "Your margin is my...
Via
StockStory
1 Volatile Stock to Target This Week and 2 We Turn Down
December 07, 2025
Market swings can be tough to stomach, and volatile stocks often experience exaggerated moves in both directions. While many thrive during risk-on environments, many also struggle to maintain investor...
Via
StockStory
Q3 Rundown: Azenta (NASDAQ:AZTA) Vs Other Drug Development Inputs & Services Stocks
November 27, 2025
As the Q3 earnings season wraps, let’s dig into this quarter’s best and worst performers in the drug development inputs & services industry, including Azenta (NASDAQ:AZTA) and its peers.
Via
StockStory
Medpace (MEDP) Q3 2025 Earnings Call Transcript
↗
November 27, 2025
Medpace (MEDP) Q3 2025 Earnings Call Transcript
Via
The Motley Fool
Topics
Earnings
Medpace (NASDAQ:MEDP): Strongest Q3 Results from the Drug Development Inputs & Services Group
November 24, 2025
As the Q3 earnings season wraps, let’s dig into this quarter’s best and worst performers in the drug development inputs & services industry, including Medpace (NASDAQ:MEDP) and its peers.
Via
StockStory
BrightSpring Health Services, 10x Genomics, QuidelOrtho, Medpace, and Fortrea Shares Are Soaring, What You Need To Know
November 24, 2025
A number of stocks jumped in the afternoon session after reports revealed the Trump administration considered extending the Affordable Care Act (ACA) subsidies. These subsidies, which are government...
Via
StockStory
Topics
Economy
Government
MEDPACE HOLDINGS INC (NASDAQ:MEDP) Shows Strong Growth and Momentum Alignment
↗
November 21, 2025
MEDP stock shows strong technical momentum and accelerating earnings growth, fitting a proven strategy for finding leading growth stocks.
Via
Chartmill
6 Healthcare Stocks With Strong Upward Momentum
↗
November 18, 2025
Via
Benzinga
2 Mooning Stocks to Research Further and 1 We Question
November 11, 2025
The stocks featured in this article have all approached their 52-week highs. When these price levels hit, it typically signals strong business execution, positive market sentiment, or significant...
Via
StockStory
Topics
Economy
Drug Development Inputs & Services Stocks Q3 Results: Benchmarking UFP Technologies (NASDAQ:UFPT)
November 11, 2025
As the Q3 earnings season wraps, let’s dig into this quarter’s best and worst performers in the drug development inputs & services industry, including UFP Technologies (NASDAQ:UFPT) and its peers.
Via
StockStory
Q3 Earnings Highs And Lows: IQVIA (NYSE:IQV) Vs The Rest Of The Drug Development Inputs & Services Stocks
November 06, 2025
As the Q3 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the drug development inputs & services industry, including IQVIA (NYSE:IQV) and its...
Via
StockStory
Drug Development Inputs & Services Stocks Q3 Recap: Benchmarking Repligen (NASDAQ:RGEN)
November 06, 2025
Earnings results often indicate what direction a company will take in the months ahead. With Q3 behind us, let’s have a look at Repligen (NASDAQ:RGEN) and its peers.
Via
StockStory
1 Mid-Cap Stock to Target This Week and 2 We Ignore
November 02, 2025
Mid-cap stocks often strike the right balance between having proven business models and market opportunities that can support $100 billion corporations. However, they face intense competition from...
Via
StockStory
3 Cash-Heavy Stocks Worth Your Attention
October 30, 2025
In a world where many businesses have shaky balance sheets, some have ignored the crowd and exercised prudence. These cash-heavy companies shine bright for their financial discipline, resilience, and...
Via
StockStory
5 Revealing Analyst Questions From Medpace’s Q3 Earnings Call
October 29, 2025
Medpace’s third quarter results were well received by the market, driven by broad-based revenue growth and robust net new business awards. Management credited strong demand across therapeutic...
Via
StockStory
Topics
Earnings
8 Analysts Assess Medpace Hldgs: What You Need To Know
↗
October 24, 2025
Via
Benzinga
Medpace Soars: AI and Data Analytics Propel Clinical Trial Giant to Record Heights
October 24, 2025
Medpace Holdings, Inc. (NASDAQ: MEDP), a leading global contract research organization (CRO), has been experiencing an unprecedented surge in its stock value, reaching an all-time high of $543.90 on...
Via
TokenRing AI
Topics
Artificial Intelligence
Why Medpace Popped 13% This Week
↗
October 24, 2025
The biopharmaceutical processor posted another strong earnings result for the third quarter.
Via
The Motley Fool
Medpace Analysts Increase Their Forecasts After Upbeat Q3 Earnings
↗
October 24, 2025
Via
Benzinga
MEDP Q3 Deep Dive: Broad-Based Growth and Strong Pipeline Fuel Upbeat Outlook
October 23, 2025
Clinical research company Medpace Holdings (NASDAQ:MEDP) reported revenue ahead of Wall Street’s expectations in Q3 CY2025, with sales up 23.7% year on year to $659.9 million. The company’s full-year...
Via
StockStory
Medpace's Q3 Earnings Beat Reflects Robust Growth And Large New Wins
↗
October 23, 2025
Medpace shares climb as Q3 earnings and revenue top estimates, driven by strong bookings, rising backlog, and an upbeat 2025 guidance.
Via
Benzinga
Topics
Earnings
Las Vegas Sands Posts Upbeat Q3 Results, Joins Garrett Motion, LendingClub, Dow, Hexcel And Other Big Stocks Moving Higher On Thursday
↗
October 23, 2025
Via
Benzinga
Topics
Stocks
12 Health Care Stocks Moving In Thursday's Pre-Market Session
↗
October 23, 2025
Via
Benzinga
Stock Market Today: Dow Jones, Nasdaq Futures Tumble Amid US-China Trade Tensions—Tesla, IBM, American Airlines In Focus
↗
October 23, 2025
U.S. stock futures were swinging on Thursday following Wednesday’s declines. Futures of major benchmark indices were lower.
Via
Benzinga
Topics
Stocks
MEDPACE HOLDINGS INC (NASDAQ:MEDP) Emerges as a Top Growth and Momentum Pick
↗
October 23, 2025
MEDP Holdings stock shows strong technical and fundamental growth momentum, meeting strict trend-following criteria for a powerful setup.
Via
Chartmill
Medpace Rockets On 'Another Strong Q' That Includes A Guidance Hike
↗
October 22, 2025
Medpace stock rocketed late Wednesday on "another strong Q," that included double-digit sales and profit growth.
Via
Investor's Business Daily
12 Health Care Stocks Moving In Wednesday's After-Market Session
↗
October 22, 2025
Via
Benzinga
Medpace Holdings Inc (NASDAQ:MEDP) Tops Q3 2025 Earnings and Revenue Estimates
↗
October 22, 2025
Medpace (MEDP) Q3 2025 earnings beat analyst forecasts with strong revenue and EPS growth. The CRO also reported robust bookings and raised its full-year guidance.
Via
Chartmill
Topics
Earnings
Medpace (NASDAQ:MEDP) Beats Q3 Sales Expectations, Stock Jumps 18.5%
October 22, 2025
Clinical research company Medpace Holdings (NASDAQ:MEDP) reported Q3 CY2025 results exceeding the market’s revenue expectations, with sales up 23.7% year on year to $659.9 million. The company’s...
Via
StockStory
Which stocks are moving after the closing bell on Wednesday?
↗
October 22, 2025
Discover the top movers in Wednesday's after-hours session and stay informed about the post-market dynamics.
Via
Chartmill
< Previous
1
2
3
4
5
6
7
8
9
...
12
13
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.